Live Chat
Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Karel Pacak, David Taïeb, editors.
    Summary: Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, and alpha radionuclide therapy, as well as the role of nanoparticles. Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.

    Contents:
    Classification of neuroendocrine tumors
    Molecular genetics of Pheochromocytoma and paraganglioma
    Molecular Genetics of MEN1-related Neuroendocrine Tumors
    Molecular genetics of MEN2-related neuroendocrine tumors
    Molecular genetics of Neuroblastoma
    Molecular Genetics of Gastroenteropancreatic Neuroendocrine Tumors
    Current and future radiopharmaceuticals in neuroendocrine tumors imaging
    SPECT/CT, PET/CT and PET/MR: Principles
    Internal dosimetry: Principles and Applications to NET
    Principles and Application of Molecular Imaging for Personalised Medicine and Guiding Interventions in Neuroendocrine Tumors
    Tumor metabolism and metabolomics of pheochromocytomas and paragangliomas
    Radionuclide imaging of pheochromocytoma and paraganglioma in the era of multi-omics
    Radionuclide imaging of Head and neck PGLs
    Radionuclide imaging of Chromaffin cell tumors
    Radionuclide imaging of Gastrointestinal neuroendocrine tumors
    Radionuclide imaging of Pancreatic neuroendocrine tumors
    Radionuclide imaging of Pulmonary, thymic neuroendocrine tumors and other neuroendocrine tumors
    Radionuclide imaging of Medullary thyroid carcinoma
    131I-MIBG therapy for pheochromocytoma/paraganglioma and neuroblastoma
    Somatostatin receptors-based radionuclide therapy
    Alpha radionuclide therapy: Principles and Applications to NET
    Nanoparticles for Radionuclide Imaging and Therapy: Principles.
    Digital Access Springer 2017
  • Article
    McGuire WL, Horwitz KB, Pearson OH, Segaloff A.
    Cancer. 1977 Jun;39(6 Suppl):2934-47.
    Breast cancer is often hormone responsive, since growth or regression of tumors can often be modulated by appropriate endocrine manipulations. Estrogen and progesterone appear to be major hormones involved in regulation of breast tumor growth. It has been recently argued that a more accurate marker of hormonal responsiveness might result if an end product of an intact estrogen response system were measured instead of the initial hormone binding step. Progesterone receptor (PgR) has been investigated in this regard since it can be readily measured in human breast tumors and there is clear evidence in experimental breast tumor model systems that PgR is under acute estrogen control. PgR is rarely found in ER- metastatic breast tumors but is present in approximately 59% of ER+ metastatic tumors, especially in those tumors with high levels of ER. Preliminary clinical correlation of ER, PgR and response to endocrine therapy is encouraging. The response rate is significantly higher if the tumor contains both ER and PgR than if the tumor contains ER alone.
    Digital Access Access Options